roflumilast,tapinarof,deucravacitinib,RGRN-305
dermavant,astrazeneca,bms,regranion
['deucra', 'roflumilast', 'deucrava', 'tapinarof']
a new pde4 inhibitor, roflumilast, was approved by the fda this year. other small molecule therapies include deucravacitinib, tapinarof, and rgrn-305.
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.